cyproheptadine has been researched along with Hyperplasia in 4 studies
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Despite an increase in bromocriptine dosage to 30 mg daily and 24 mg/day cyproheptadine, the clinical and biochemical remission was not sustained in patient 1, and no further improvement occurred in patient 2." | 5.28 | Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland. ( Croughs, RJ; Koppeschaar, HP; McNicol, AM; van't Verlaat, JW, 1989) |
| " Despite an increase in bromocriptine dosage to 30 mg daily and 24 mg/day cyproheptadine, the clinical and biochemical remission was not sustained in patient 1, and no further improvement occurred in patient 2." | 1.28 | Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland. ( Croughs, RJ; Koppeschaar, HP; McNicol, AM; van't Verlaat, JW, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Modlin, IM | 1 |
| Tang, LH | 1 |
| Lawton, GP | 1 |
| Darr, UM | 1 |
| Zhu, ZH | 1 |
| Soroka, CJ | 1 |
| McPherson, HT | 1 |
| Krieger, DT | 1 |
| Croughs, RJ | 1 |
| Koppeschaar, HP | 1 |
| van't Verlaat, JW | 1 |
| McNicol, AM | 1 |
1 review available for cyproheptadine and Hyperplasia
| Article | Year |
|---|---|
Cushing's syndrome.
Topics: Adolescent; Adrenal Cortex Function Tests; Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrena | 1977 |
3 other studies available for cyproheptadine and Hyperplasia
| Article | Year |
|---|---|
Enterochromaffin-like cell pathobiology of mastomys.
Topics: Animals; Chromogranins; Cyproheptadine; Enterochromaffin Cells; Estradiol; Gastric Mucosa; Gastrins; | 1994 |
The central nervous system and Cushing's disease.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenal Glands; Adrenocorticotropic Hormone; Central Nervous Syste | 1978 |
Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland.
Topics: Adolescent; Adrenocorticotropic Hormone; Bromocriptine; Cushing Syndrome; Cyproheptadine; Humans; Hy | 1989 |